Downregulation of SELENBP1 enhances oral squamous cell carcinoma chemoresistance through KEAP1 –NRF2 signaling
ConclusionSENENBP1 is identified as a novel protective biomarker for OSCC patients. Targeting at the miR-4786-3p –SELENBP1–KEAP1–NRF2 signaling axis may enhance the efficacy of chemotherapy for OSCC.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Databases & Libraries | Drugs & Pharmacology | Oral Cancer | Selenium | Skin Cancer | Squamous Cell Carcinoma | Study